Torna all'elenco degli studi

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)

CODICE STUDIO

NCT05455320

TIPOLOGIA

Ricaduti

NOME SPONSOR

Janssen Reasearch&Development, LLc

DESCRIZIONE

Trattamento

Experimental: Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)

Participants will receive Talquetamab and Daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication.

Leggi tutto

FARMACI UTILIZZATI

Daratumumab, Pomalidomide, Desametasone, Talquetamab (CAR-T)